Castle Biosciences Announces Third Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Castle Biosciences Inc. (CSTL) Misses Q3 EPS by 7c
November 8, 2021 4:33 PM ESTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q3 EPS of ($0.47), $0.07 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $22.97 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2021 revenue of $89-93 million, versus the... More
